Literature DB >> 19735646

Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo.

Preetha Anand1, Hareesh B Nair, Bokyung Sung, Ajaikumar B Kunnumakkara, Vivek R Yadav, Rajeshwar R Tekmal, Bharat B Aggarwal.   

Abstract

Curcumin, a yellow pigment present in the spice turmeric (Curcuma longa), has been linked with antioxidant, anti-inflammatory, antiproliferative, anticancer, antidiabetic, antirheumatic, and antiviral effects, but its optimum potential is limited by its lack of solubility in aqueous solvents and poor oral bioavailability. We employed a polymer-based nanoparticle approach to improve bioavailability. Curcumin was encapsulated with 97.5% efficiency in biodegradable nanoparticulate formulation based on poly (lactide-co-glycolide) (PLGA) and a stabilizer polyethylene glycol (PEG)-5000. Dynamic laser light scattering and transmission electron microscopy indicated a particle diameter of 80.9 nm. This curcumin, renamed from hereon "as curcumin (NP)", was characterized for its biological activity. In vitro curcumin (NP) exhibited very rapid and more efficient cellular uptake than curcumin. Estrase staining revealed that curcumin (NP) was at least as potent as or more potent than curcumin in inducing apoptosis of leukemic cells and in suppressing proliferation of various tumor cell lines. When examined by electrophoretic gel shift mobility assay, curcumin (NP) was more active than curcumin in inhibiting TNF-induced NF-kappaB activation and in suppression of NF-kappaB-regulated proteins involved in cell proliferation (cyclin D1), invasion (MMP-9), and angiogenesis (VEGF). In mice, curcumin (NP) was more bioavailable and had a longer half-life than curcumin. Overall we demonstrate that curcumin-loaded PLGA nanoparticles formulation has enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo over curcumin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19735646      PMCID: PMC3181156          DOI: 10.1016/j.bcp.2009.09.003

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  40 in total

1.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

Authors:  William J Gradishar; Sergei Tjulandin; Neville Davidson; Heather Shaw; Neil Desai; Paul Bhar; Michael Hawkins; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2005-09-19       Impact factor: 44.544

2.  Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance.

Authors:  Ricky A Sharma; Stephanie A Euden; Sharon L Platton; Darren N Cooke; Aisha Shafayat; Heather R Hewitt; Timothy H Marczylo; Bruno Morgan; David Hemingway; Simon M Plummer; Munir Pirmohamed; Andreas J Gescher; William P Steward
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

3.  Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration.

Authors:  I Bala; V Bhardwaj; S Hariharan; S V Kharade; N Roy; M N V Ravi Kumar
Journal:  J Drug Target       Date:  2006-01       Impact factor: 5.121

4.  Curcumin: getting back to the roots.

Authors:  Shishir Shishodia; Gautam Sethi; Bharat B Aggarwal
Journal:  Ann N Y Acad Sci       Date:  2005-11       Impact factor: 5.691

5.  Interaction of curcumin with phosphatidylcholine: A spectrofluorometric study.

Authors:  G Began; E Sudharshan; K Udaya Sankar; A G Appu Rao
Journal:  J Agric Food Chem       Date:  1999-12       Impact factor: 5.279

6.  Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.

Authors:  Anjana Bhardwaj; Gautam Sethi; Saroj Vadhan-Raj; Carlos Bueso-Ramos; Yasunari Takada; Upasna Gaur; Asha S Nair; Shishir Shishodia; Bharat B Aggarwal
Journal:  Blood       Date:  2006-12-12       Impact factor: 22.113

7.  Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.

Authors:  Tae-You Kim; Dong-Wan Kim; Jae-Yong Chung; Sang Goo Shin; Sung-Chul Kim; Dae Seog Heo; Noe Kyeong Kim; Yung-Jue Bang
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

8.  A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS.

Authors:  L Mu; S S Feng
Journal:  J Control Release       Date:  2003-01-09       Impact factor: 9.776

Review 9.  Curcumin as "Curecumin": from kitchen to clinic.

Authors:  Ajay Goel; Ajaikumar B Kunnumakkara; Bharat B Aggarwal
Journal:  Biochem Pharmacol       Date:  2007-08-19       Impact factor: 5.858

10.  Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

Authors:  P A Vasey; S B Kaye; R Morrison; C Twelves; P Wilson; R Duncan; A H Thomson; L S Murray; T E Hilditch; T Murray; S Burtles; D Fraier; E Frigerio; J Cassidy
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

View more
  121 in total

Review 1.  Dietary agents in cancer prevention: an immunological perspective.

Authors:  Ya Ying Zheng; Bharathi Viswanathan; Pravin Kesarwani; Shikhar Mehrotra
Journal:  Photochem Photobiol       Date:  2012-03-30       Impact factor: 3.421

Review 2.  Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Subhash Padhye
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

3.  Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer.

Authors:  Savita Bisht; Masamichi Mizuma; Georg Feldmann; Niki A Ottenhof; Seung-Mo Hong; Dipankar Pramanik; Venugopal Chenna; Collins Karikari; Rajni Sharma; Michael G Goggins; Michelle A Rudek; Rajani Ravi; Amarnath Maitra; Anirban Maitra
Journal:  Mol Cancer Ther       Date:  2010-07-20       Impact factor: 6.261

4.  Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century.

Authors:  Wing-Hin Lee; Ching-Yee Loo; Mary Bebawy; Frederick Luk; Rebecca S Mason; Ramin Rohanizadeh
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

Review 5.  Regulating miRNA by natural agents as a new strategy for cancer treatment.

Authors:  Sajiv Sethi; Yiwei Li; Fazlul H Sarkar
Journal:  Curr Drug Targets       Date:  2013-09       Impact factor: 3.465

6.  A genetically engineered thermally responsive sustained release curcumin depot to treat neuroinflammation.

Authors:  S Michael Sinclair; Jayanta Bhattacharyya; Jonathan R McDaniel; David M Gooden; Ramesh Gopalaswamy; Ashutosh Chilkoti; Lori A Setton
Journal:  J Control Release       Date:  2013-07-03       Impact factor: 9.776

7.  Encapsulation of curcumin in self-assembling peptide hydrogels as injectable drug delivery vehicles.

Authors:  Aysegul Altunbas; Seung J Lee; Sigrid A Rajasekaran; Joel P Schneider; Darrin J Pochan
Journal:  Biomaterials       Date:  2011-05-23       Impact factor: 12.479

8.  Anti-Inflammatory Effects of Novel Standardized Solid Lipid Curcumin Formulations.

Authors:  Pragati P Nahar; Angela L Slitt; Navindra P Seeram
Journal:  J Med Food       Date:  2014-12-09       Impact factor: 2.786

9.  Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 mice.

Authors:  Kwok Kin Cheng; Chin Fung Yeung; Shuk Wai Ho; Shing Fung Chow; Albert H L Chow; Larry Baum
Journal:  AAPS J       Date:  2012-12-11       Impact factor: 4.009

10.  Anticancer Potentials of Root Extract of Polygala senega and Its PLGA Nanoparticles-Encapsulated Form.

Authors:  Saili Paul; Soumya Sundar Bhattacharyya; Naoual Boujedaini; Anisur Rahman Khuda-Bukhsh
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-21       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.